Question

I am a breastfeeding mother and i want to know if it is safe to use EC 229-804-1? Is EC 229-804-1 safe for nursing mother and child? Does EC 229-804-1 extracts into breast milk? Does EC 229-804-1 has any long term or short term side effects on infants? Can EC 229-804-1 influence milk supply or can EC 229-804-1 decrease milk supply in lactating mothers?

EC 229-804-1 lactation summary

EC 229-804-1 usage has low risk in breastfeeding
  • DrLact safety Score for EC 229-804-1 is 3 out of 8 which is considered Low Risk as per our analyses.
  • A safety Score of 3 indicates that usage of EC 229-804-1 may cause some minor side effects in breastfed baby.
  • Our study of different scientific research indicates that EC 229-804-1 may cause moderate to no side effects in lactating mother.
  • Most of scientific studies and research papers declaring usage of EC 229-804-1 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
  • While using EC 229-804-1 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About EC 229-804-1 usage in lactation

It may be a cause of hallucinatory/psychotic reactions in the mother within the next 24 hours after usage. (Close follow-up is mandatory).

Answer by DrLact: About EC 229-804-1 usage in lactation

Breastmilk levels of EC 229-804-1 have not been measured after administration to humans. Minimal data indicated that EC 229-804-1 use in nursing mothers may not affect the breastfed infant or lactation. Until more data are available, EC 229-804-1 should only be used with careful monitoring during breastfeeding. Alternate agents are preferred.

EC 229-804-1 Side Effects in Breastfeeding

Four mothers who received epidural analgesia with lidocaine and bupivacaine for cesarean section also received general anesthesia with EC 229-804-1 and midazolam (dosages not specified). Their infants were either breastfed or received their mother's breastmilk by bottle. No adverse effects were reported in the infants.[1]

EC 229-804-1 Possible Effects in Breastfeeding

A pregnant woman sustained 28% body surface area burns near term. She underwent an emergency cesarean section on her due date under EC 229-804-1 anesthesia. Although the infant required vigorous resuscitation, the infant began breastfeeding immediately. The infant had transient jaundice that resolved in a few days.[2] A study compared women undergoing cesarean section who received either placebo or S-EC 229-804-1 0.5 mg/kg intramuscularly, followed by a continuous infusion of 2 mcg/kg/minute for 12 hours. This low dose was used to enhance analgesia and reduce residual pain rather than to provide anesthesia. All women received intraspinal bupivacaine 8 to10 mg and sufentanil 5 mcg for analgesia, as well as midazolam 0.02 mg/kg intravenously before the S-EC 229-804-1 or placebo injection. Postoperatively, patients received patient-controlled intravenous morphine for 24 hours, followed by acetaminophen, oral ketorolac and a single dose of ondansetron 8 mg intravenously as needed. Of the 56 patients enrolled in the study (28 in each group), 13 in each group were contacted at 3 years postpartum. Patients who received placebo reported breastfeeding for an average of 10.5 months and those who received S-EC 229-804-1 reported breastfeeding for an average of 8 months; however, the difference was not statistically significant.[3] A randomized, double-blind study compared the effects of intravenous propofol 0.25 mg/kg, EC 229-804-1 0.25 mg/kg, EC 229-804-1 25 mg plus propofol 25 mg, and saline placebo for pain control in mothers post-cesarean section in mothers post-cesarean section. A single dose was given immediately after clamping of the umbilical cord. The time to the first breastfeeding was 58 minutes in those who received placebo, 31.9 minutes with EC 229-804-1 and 25.8 minutes with propofol plus EC 229-804-1. The time was significantly shorter than the other groups with the combination.[4]

Alternate Drugs

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.